Clinical review report Travoprost 0.003% (Izba) (Novartis Pharmaceuticals Canada Inc. on behalf of Icon Canada Inc.)
The objective of the review was to identify, summarize, and critically assess the beneficial and harmful effects of travoprost 0.003% PQ for the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma(OAG).
| Autor principal: | |
|---|---|
| Autor Corporativo: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Ottawa, Ontario :
Canadian Agency for Drugs and Technologies in Health
2017.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820281306719 |
| Sumario: | The objective of the review was to identify, summarize, and critically assess the beneficial and harmful effects of travoprost 0.003% PQ for the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma(OAG). |
|---|---|
| Descripción Física: | 1 online resource (1 PDF file (48 pages)) : illustrations |
